MeSH tree: C23.550.291.500.483
Scientists at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and collaborators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved ...
Jul 28, 2026
0
7
Triplet therapy with pirtobrutinib, venetoclax and rituximab as a two-year fixed-duration therapy improves progression-free survival for patients with relapsed/refractory chronic lymphocytic leukemia (CLL) compared with standard-of-care ...
Jun 15, 2026
0
4
Treatment with so-called BTK inhibitors has improved the prognosis for people with chronic lymphocytic leukemia (CLL). At the same time, these drugs affect the immune system and may cause side effects over time, according ...
May 26, 2026
0
6
Scientists at St. Jude Children's Research Hospital, the American Society for Hematology (ASH) and the Munich Leukemia Laboratory have developed a data-sharing platform that unites genomics, gene expression and clinical information ...
Apr 6, 2026
0
4
The U.S. Food and Drug Administration has approved an expanded indication for Eli Lilly's Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults with relapsed or refractory ...
Dec 10, 2025
0
11
In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine ...
Dec 9, 2025
0
7
According to a new trial, patients with chronic lymphocytic leukemia (CLL) show comparable outcomes whether they receive a single-agent treatment indefinitely or a combination treatment for a fixed period of time.
Dec 8, 2025
0
14
Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. ...
Dec 8, 2025
0
5
Researchers at the University of Eastern Finland and their international collaborators have identified key developmental and molecular differences between the two main subtypes of chronic lymphocytic leukemia, CLL. The findings, ...
Nov 18, 2025
0
23
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States.
Nov 6, 2025
0
20
